S.Biomedics Co., Ltd. (KOSDAQ:304360)

Market Cap	286.01B
Revenue (ttm)	13.73B
Net Income (ttm)	-6.69B
Shares Out	11.75M
EPS (ttm)	-582.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,187
Average Volume	164,417
Open	25,200
Previous Close	25,500
Day's Range	23,750 - 26,000
52-Week Range	11,110 - 51,600
Beta	n/a
RSI	47.90
Earnings Date	Mar 21, 2025

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 53
• Stock Exchange: KOSDAQ
• Ticker Symbol: 304360

Financial Performance

In 2023, S.Biomedics's revenue was 13.11 billion, an increase of 8.22% compared to the previous year's 12.11 billion. Losses were -7.52 billion, 18.9% more than in 2022.